IL-6-inhibitors, such as the humanized monoclonal antibody (tocilizumab), are approved for the treatment of rheumatoid arthritis [14], but beneficial effects of cytokine-blockade drugs to improve outcome in sepsis has yet to be demonstrated. This evidence concerns the gene IL6 and Sepsis.